Harnessing deep learning and lab automation to accelerate drug discovery in targeted protein degradation.
Celeris Therapeutics has raised $9.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2022.
Celeris Therapeutics's investors include European Innovation Council, R42 Group, Longevitytech.fund, APEX Ventures, Pace Ventures.
Celeris Therapeutics is headquartered in Menlo Park, United States.
Harnessing deep learning and lab automation to accelerate drug discovery in targeted protein degradation.
Celeris Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Celeris Therapeutics — Funding & Investors." VCBacked, October 19, 2022, https://www.vcbacked.co/company/celeris-therapeutics. Accessed August 14, 2026.
VCBacked. (2022). Celeris Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/celeris-therapeutics
{{cite web |title=Celeris Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/celeris-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated